X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New medicines are part of the solution to hold down future health care costs

By Amey Sutkowski  |    June 28, 2017
Innovative medicines improve patient outcomes and can yield significant economic savings. The introduction of a medicine by 2020 that delays the onset of Alzheimer’s disease by just five years would...   Read More

More than 50 medicines and vaccines in development for HIV infection, treatment and prevention

By Andrew Powaleny  |    June 27, 2017
From the introduction of anti-retroviral therapy (ART) in the mid-1990’s, to the discovery of medicines that prevent the transmission of HIV, America’s biopharmaceutical companies are leading the ...   Read More

New data put medicine costs and spending in context

By Holly Campbell  |    June 26, 2017
We are in a new era of medicine where breakthrough science is transforming patient care and enabling us to more effectively treat chronic diseases, like cancer and diabetes, which are the biggest...   Read More

Medicare Monday: 3 reasons why repealing Part D’s noninterference clause is a bad idea

By Nicole Longo  |    June 26, 2017
A number of proposals have been thrown around as part of the health care debate. One idea is to repeal the noninterference clause in Medicare Part D. Doing so would allow the Secretary of Health and...   Read More

Ask About Adherence: Discussion on medication adherence as national priority

By Guest Contributor  |    June 21, 2017
Ask About Adherence is a blog series featuring discussions with experts and new medication adherence resources. In this post, Sloane Salzburg, M.S, executive director of Prescriptions for a Healthy...   Read More

340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B

By Nicole Longo  |    June 20, 2017
In case you missed it, the Atlanta Journal-Constitution analyzed data on hospital participation in the 340B program in Georgia and found that some hospitals are raking in huge profits – with no...   Read More

Medicare Monday: How government price setting in Part D could reduce innovation, shorten life expectancy for beneficiaries

By Nicole Longo  |    June 19, 2017
Today, we are diving into the conversation about how government price setting proposals could impact the Medicare Part D program and beneficiaries. Imposing Veterans Administration (VA)-style pricing...   Read More

In the OECD other health care services will be ten times prescription medicine spending growth over next decade

By Kevin Haninger  |    June 14, 2017
Now more than ever, innovative therapies are transforming care and providing cures for patients fighting life-threatening diseases.  In the midst of this medical progress, other health care...   Read More

As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority

By Mark Grayson  |    June 13, 2017
Yesterday, PhRMA filed comments on negotiating objectives for the modernization of the North American Free Trade Agreement (NAFTA). The Administration’s review of our trading relationship with Mexico...   Read More

Examining the brain in The New Era of Medicine

By Andrew Powaleny  |    June 13, 2017
Biopharmaceutical innovation is powering a rapid pace of medical breakthroughs and scientific advancements.  America’s biopharmaceutical companies are working day in and day out to uncover new...   Read More

Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines

By Nicole Longo  |    June 12, 2017
We’ve seen significant progress in recent years in the treatment of cancer, and that progress is expected to continue. A new report released this month found that there are more than 240 new...   Read More

Fact Check Friday: The truth about IPAB

By Nicole Longo  |    June 9, 2017
This week on Fact Check Friday, we’re taking a closer look at the Independent Payment Advisory Board (IPAB) – the panel tasked with proposing cuts to Medicare if spending exceeds a certain growth...   Read More

Modernizing FDA regulations to advance a value-driven health care system

By Michelle Drozd  |    June 8, 2017
A modern regulatory framework is the foundation of an innovative health care system that allows stakeholders to work together to deliver better outcomes for patients. To advance critical regulations...   Read More

Opening the conversation around mental health treatment with advocates & industry leaders

By Andrew Powaleny  |    June 6, 2017
Biopharmaceutical research and innovation is making strides in the world of mental health by expanding the understanding of the field and bringing about a new era of mental health medicine. No longer...   Read More

Foreign government price setting by any name harms innovation and access to medicines

By Kevin Haninger  |    June 6, 2017
In an effort to contain health care spending, some foreign governments mandate prices for innovative medicines at levels below the value they provide to patients, health care systems, and the wider...   Read More

Medicare Monday: Positive impact of Part D on America’s seniors

By Nicole Longo  |    June 5, 2017
Implementation of Medicare Part D significantly increased access to medicines for seniors and for those under age 65 with permanent disabilities. Since then, Part D has contributed to significant...   Read More

PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines

By Holly Campbell  |    June 2, 2017
    The following op-ed was authored by PhRMA president and CEO Stephen J. Ubl and published on Forbes here on June 2, 2017. The way our health care system currently pays for prescription medicines...   Read More

A critical opportunity to prevent prescription drug abuse

By Anne McDonald Pritchett, PhD  |    June 2, 2017
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb recently cited addressing the opioid crisis as his highest priority. As someone who has spent the bulk of my career focused on...   Read More

Celebrating PRIDE in biopharmaceutical science

By Andrew Powaleny  |    June 1, 2017
Today marks the beginning of Lesbian, Gay, Bisexual, and Transgender (LGBT) Pride Month and we are proud to join with our member companies in celebrating our support for the LGBT community. We...   Read More

More than 240 immuno-oncology treatments in development to fight cancer

By Andrew Powaleny  |    June 1, 2017
The American Cancer Society estimates that in 2017 alone, there will be more than 1.6 million new cases of cancer and 600,000 cancer deaths in the United States. With estimates like these, the need...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."